Skip to main content

10-22-2021 | Healthcare costs | News

SGLT2 inhibitor cost-effectiveness feasible in low-, middle-income countries

Author: Laura Cowen


medwireNews: Reducing the cost of sodium-glucose cotransporter (SGLT)2 inhibitors by around 17% would make them cost-effective for use in people with type 2 diabetes in low- and middle-income countries (LMICs), study findings indicate.

The cost of glucagon-like peptide (GLP)-1 inhibitors, however, would need to fall by more than 98% for them to be a cost-effective second-line alternative to sulfonylureas, report Sanjay Basu (Station Health, San Francisco, California, USA) and co-authors in The Lancet Diabetes & Endocrinology.

Basu and team used individual-level data for 23,678 people with diabetes from 67 LMICs to create a microsimulation to calculate the effect switching from sulfonylureas to alternative agents or from human insulin to insulin glargine would have on disability-adjusted life–years (DALYs) and the costs of cardiovascular events, heart failure, end-stage renal disease, vision loss, pressure sensation loss, severe hypoglycemia, and drug-specific side-effects.

They estimated that, among the countries studied, a 1-year supply of metformin 500 mg/day costs a median of US$ 24 (€ 21). The median costs of a sulfonylurea (gliclazide 80 mg/day), SGLT2 inhibitor (empagliflozin 5 mg/day), and GLP-1 receptor agonist (liraglutide 1.2 mg/day) were $ 26 (€ 22), $ 271 (€ 232), and $12,378 (€ 10,615), respectively. For human insulin, the median cost was $ 10 (€ 9) per 10 mL vial of 100 IU/mL while for glargine it was $ 29 (€ 25) per 10 mL vial of 100 IU/mL.

However, to be cost-effective relative to second-line sulfonylurea therapy, with a price per DALY averted of less than three times the national gross domestic product per capita, SGLT2 inhibitors would need to have a median price of $ 224 (€192) per person per year, a 17.4% cost reduction.

Commenting on the findings in a linked article, Ranjit Unnikrishnan and Viswanathan Mohan, both from Madras Diabetes Research Foundation in Chennai, India, say: “A price reduction of this magnitude is eminently feasible once these agents go off patent; indeed, this situation has already arisen with dapagliflozin in India, where generic brands that are more than 50% cheaper than the original have been introduced.”

But GLP-1 receptor agonists would need to cost a median $ 208 (€ 178) per person per year to be cost-effective relative to second-line sulfonylurea therapy, equivalent to a 98.3% reduction, which Unnikrishnan and Viswanathan say “seems too high to be practical and is unlikely to be achieved even if these molecules go off patent.”

For insulin glargine to be a cost-effective replacement for human insulin, the median cost would need to fall by 31.0% to $ 20 (€ 17) per vial, according to the investigators.

Basu and team also looked at a glycemia-agnostic pathway where SGLT2 inhibitors and GLP-1 receptor agonists were added to existing therapies among people with a history of heart or kidney disease. This approach produced a fourfold greater impact on DALYs compared with the use of these agents as sulfonylurea substitutes, with 92% and 72% reductions in incremental cost-effectiveness ratios for SGLT2 inhibitors and GLP-1 receptor agonists, respectively. Indeed, in this case, no price reduction would be needed to make SLGT2 inhibitors cost-effective.

The authors conclude: “Our estimates provide important context and potential targets for policy makers, for whom cost has been cited as a key barrier to the inclusion of SGLT2 inhibitors and GLP-1 receptor agonists in treatment guidelines.”

They add that the data “support the broader inclusion of such therapies in practice, particularly through a glycaemia-agnostic treatment pathway.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Lancet Diabetes Endocrinol 2021; doi:10.1016/S2213-8587(21)00240-0
Lancet Diabetes Endocrinol 2021; doi:10.1016/S2213-8587(21)00264-3


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »